Center François Baclesse / Centre Régional de Lutte contre le Cancer François Baclesse (CRLCC)

Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review (2026) Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, et al. Journal article Radiobiology Contributions and Perspectives in Hadron Therapy, With a Focus on Carbon Ions: Report From the Workshop Hadron Therapy for Life, Caen, March 2025 (2026) Haghdoost S, Thariat J, Toma-Dasu I, Frey B, Rodriguez-Lafrasse C, Valable S, Laurent C, et al. Journal article Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial (2025) Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, et al. Journal article Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2024) Hadoux J, Lamarca A, Grande E, Deandreis D, Kaltsas G, Janson ET, Tombal B, et al. Journal article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article Salvage total glossectomy and total glosso-laryngectomy: Are they worth it? A GETTEC French multicenter study. (2022) Mazerolle P, Fuchsmann C, Schultz P, Benmoussa N, Malard O, Bozec A, Deneuve S, et al. Journal article Salivary Gland Carcinoma in Children and Adolescents: The Expert/Partner Diagnosis and Treatment Recommendations (2021) Bisogno G, Schneider D, Ferrari A, Stachowicz-Stencel T, Rascon J, Synakiewicz A, Agaimy A, et al. Conference contribution Salivary gland carcinoma in children and adolescents: The EXPeRT/PARTNER diagnosis and treatment recommendations (2021) Surun A, Schneider DT, Ferrari A, Stachowicz-Stencel T, Rascon J, Synakiewicz A, Agaimy A, et al. Journal article Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial (2021) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article